Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ
$84.91
▼ DOWN 4.15% (-3.68)

KEY STATISTICS

Market Cap$11.96 B
52w High$95.49
52w Low$22.73
Dividend Yield—
Frequency—
P/E-37.74
Volume1.28M
Shares Out.140.86M

COMPANY

LEADERSHIP

Christopher R. Anzalone
CHIEF EXECUTIVE
Christopher R. Anzalone

COMPENSATION 2026

Salary$981,046
Stock Awards$6,810,292
Incentive Plan Pay$1,236,000
All Other Comp.$2,523
Total$9,029,861

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 16, 1993
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
711

PRICE TARGET

Target High$126.00
Target Low$46.00
Target Median$117.50
Target Consensus$105.17

UPCOMING EARNINGS

DateNov 24, 2026
DayTuesday
Rev. Est.$71.76M
NOV
24
TUE

SPLIT RECORD

DATETYPERATIO
2011-11-17Reverse1:10
2004-01-20Reverse1:65
2004-01-15Reverse1:65

PRICE

$84.91 ▼ DOWN 4.15% (−$3.68)
OVERLAYS
$84.00$85.50$87.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM84.91

About Arrowhead Pharmaceuticals, Inc.

https://arrowheadpharma.com ↗

Arrowhead Pharmaceuticals, Inc. develops RNAi-based medicines for intractable diseases, with multiple candidates in clinical trials and collaborations with Janssen and Takeda.

INDUSTRY

Biotechnology

A PRODUCT ARROWHEAD PHARMACEUTICALS, INC. IS KNOWN FOR

REDEMPLO® (plozasiran)
REDEMPLO® (plozasiran)

REDEMPLO® is an RNAi therapeutic by Arrowhead that reduces APOC3 to treat familial chylomicronemia syndrome, marking their first commercial product and a milestone in rare genetic disorder treatment.

COMPETITORS

COMPETITOR
ALNY COMPARE
AMRN COMPARE
CRSP COMPARE
IONS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
254
LISTED HERE
26
RANKED BY POSITION SIZE
XAW.TO
0.01% · 4.9M
VTI
0.02% · 4.3M
XMMO
2.11% · 1.8M
XBI
1.11% · 1.5M
SCHA
0.26% · 668.8K
FCMO.TO
1.40% · 295.8K
FXH
1.74% · 227.9K
DFAS
0.10% · 175.3K
ADPV
5.15% · 105.9K
JSMD
0.82% · 99.9K
QMOM
1.98% · 97.1K
JMEE
0.29% · 96.6K
DOCG.L
1.93% · 71.7K
JHMM
0.10% · 70.8K
TMSL
0.18% · 61.9K
LABU
0.76% · 54.4K
FRTY
3.05% · 53.6K
USVM
0.22% · 44.6K
GNOM
3.43% · 36.9K
VETS
1.48% · 24.8K
TILT
0.09% · 24.5K
BKMC
0.26% · 20.1K
BBP
1.46% · 19.6K
HTEC
1.92% · 17.0K
IQSM
0.38% · 15.4K
RECS
0.02% · 11.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
76.05%
HOLDERS
664
TOP 12 OF 664 · RANKED BY POSITION SIZE
Blackrock, Inc.
21.3M sh · $1.42B
Vanguard Group Inc
16.0M sh · $553.08M
Blackrock Inc.
15.7M sh · $407.61M
Avoro Capital Advisors LLC
11.4M sh · $925.59M
Fmr LLC
8.0M sh · $655.32M
Oppenheimerfunds, Inc.
7.8M sh · $143.19M
State Street Corp
6.5M sh · $407.31M
Slate Path Capital LP
5.0M sh · $171.83M
Geode Capital Management, LLC
4.3M sh · $274.5M
Norges Bank
3.9M sh · $317.61M
Invesco Ltd.
3.9M sh · $316.58M
Fred Alger Management, LLC
3.3M sh · $209.57M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-01-31

INSIDER TRADES

★
DIRECTOR
OLUKOTUN ADEOYE Y
Sale · 2.0K shares
2026-08-18
★
DIRECTOR
PERRY MICHAEL S
Sale · 11.6K shares
2026-08-18
★
DIRECTOR
Cohen Matthew Gregory
— · —
2026-06-15
★
DIRECTOR
Cohen Matthew Gregory
Purchase · 11.9K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 3
MARKET PERFORM 2
OUTPERFORM 1
NEUTRAL 1
11 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY B. Riley Securities BUY Morgan Stanley OVERWEIGHT Piper Sandler OVERWEIGHT Chardan Capital BUY JP Morgan OVERWEIGHT Leerink Partners MARKET PERFORM Bernstein MARKET PERFORM

SECTORS PEERS

PEERPRICE
KRYS$351.46COMPARE
AXSM$199.02COMPARE
KYMR$118.15COMPARE
PCVX$59.84COMPARE
TGTX$53.93COMPARE
ALKS$47.41COMPARE
PTCT$70.09COMPARE
CRSP$57.72COMPARE